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We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola
vaccination regimen in healthy and HIV-infected adults with different intervals between
Ebola vaccinations.
Methods and findings
In this randomised, observer-blind, placebo-controlled Phase II trial, 668 healthy 18- to 70-
year-olds and 142 HIV-infected 18- to 50-year-olds were enrolled from 1 site in Kenya and 2
sites each in Burkina Faso, Cote d’Ivoire, and Uganda. Participants received intramuscular
Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. Females
represented 31.4% of the healthy adult cohort in contrast to 69.7% of the HIV-infected
cohort. A subset of healthy adults received booster vaccination with Ad26.ZEBOV or saline
at Day 365. Following vaccinations, adverse events (AEs) were collected until 42 days post
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last vaccination and serious AEs (SAEs) were recorded from signing of the ICF until the end
of the study. The primary endpoint was safety, and the secondary endpoint was immunoge-
nicity. Anti-Ebola virus glycoprotein (EBOV GP) binding and neutralising antibodies were
measured at baseline and at predefined time points throughout the study.
The first participant was enrolled on 9 November 2015, and the date of last participant’s
last visit was 12 February 2019. No vaccine-related SAEs and mainly mild-to-moderate AEs
were observed among the participants. The most frequent solicited AEs were injection-site
pain (local), and fatigue, headache, and myalgia (systemic), respectively. Twenty-one days
post-MVA-BN-Filo vaccination, geometric mean concentrations (GMCs) with 95% confi-
dence intervals (CIs) of EBOV GP binding antibodies in healthy adults in 28-, 56-, and 84-
day interval groups were 3,085 EU/mL (2,648 to 3,594), 7,518 EU/mL (6,468 to 8,740), and
7,300 EU/mL (5,116 to 10,417), respectively. In HIV-infected adults in 28- and 56-day inter-
val groups, GMCs were 4,207 EU/mL (3,233 to 5,474) and 5,283 EU/mL (4,094 to 6,817),
respectively. Antibody responses were observed until Day 365. Ad26.ZEBOV booster vacci-
nation after 1 year induced an anamnestic response.
Study limitations include that some healthy adult participants either did not receive dose
2 or received dose 2 outside of their protocol-defined interval and that the follow-up period
was limited to 365 days for most participants.
Conclusions
Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy
and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56
days improved the magnitude of humoral immune responses. Antibody levels persisted to
at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vacci-
nation-induced immune memory. These data supported the approval by the European




Why was this study done?
• With Ebola outbreaks increasing, there is an unmet medical need for a prophylactic vac-
cine to prevent and mitigate Ebola outbreaks.
• To address the urgent medical need during the 2014 to 2016 outbreak, the clinical devel-
opment of the 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo
was accelerated. This Phase II study was part of this accelerated program, evaluating the
safety and immunogenicity of the 2-dose vaccine regimen in healthy and HIV-infected
African adults, with 28-, 56-, and 84-day intervals between doses.
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• The study was amended to evaluate safety and immunogenicity of a booster vaccination
with Ad26.ZEBOV, administered approximately 1 year after the first vaccination, in
healthy adults.
What did the researchers do and find?
• We conducted a randomised trial to assess the safety and the immunogenicity of the
Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in 3 different vaccination intervals in
healthy and HIV-infected adults.
• The vaccine regimen was well tolerated and induced marked immune responses; the
highest humoral responses were observed after vaccination with 56-day and 84-day
intervals.
• Anamnestic responses were observed in all healthy participants receiving Ad26.ZEBOV
as booster at 1 year after the first dose.
What do these findings mean?
• Our results demonstrate that the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen is safe
and immunogenic in healthy and HIV-infected adults and induces immune memory
that can rapidly be reactivated.
• Our findings support the prophylactic use of the 2-dose Ad26.ZEBOV, MVA-BN-Filo
vaccine regimen against Ebola infection in African adult populations.
• The 2-dose vaccine regimen comprising of Ad26.ZEBOV and MVA-BN-Filo has
received marketing authorisation under exceptional circumstances for prophylactic use
against EVD in adults and children�1 year old within the European Union.
Introduction
Since its first identification as the cause of a haemorrhagic fever in 1976, Ebola virus (EBOV)
has become increasingly recognised as a widely dispersed pathogen across the African conti-
nent [1], with an increasing number of outbreaks. In most cases, infection starts with nonspe-
cific influenza-like symptoms—fatigue, myalgia, arthralgia, headache, and fever. These may be
followed by more severe clinical manifestations ultimately leading to multi-organ dysfunction,
vascular leakage, and intense generalised bleeding resulting in death within 5 to 8 days of
symptom onset [2]. In the biggest outbreak to date in Guinea, Liberia and Sierra Leone in 2014
to 2016, there were 28,616 cases and 11,310 deaths [3]. The 10th outbreak in Democratic
Republic of the Congo (DRC) from 2018 to 2020 in the Kivu area was the second largest in his-
tory with 3,470 cases, including 2,287 deaths [4,5]. Several EBOV vaccines are in development
[6] and target the viral surface glycoprotein (GP). The main difference between vaccines is the
vector used to deliver the antigen. In a ring vaccination strategy, efficacy is assessed through
the vaccination of contacts, and contacts of contacts, of individuals with confirmed cases of
EBOV disease. This strategy was applied in the 2014 to 2016 West African outbreak in Guinea
and the 2018 to 2020 DRC outbreak, in which 1 dose of a recombinant replication-competent
PLOS MEDICINE Phase II trial of Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in Africa
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003813 October 29, 2021 3 / 22
vesicular stomatitis viral vectored vaccine (rVSV-ZEBOV-GP) expressing the GP of the Kikwit
variant of the Zaire species demonstrated 100% [7] and 97.5% [8] efficacy from 10 days after
vaccination, respectively. This vaccine (Ervebo) has been approved by the Food and Drug
Administration (FDA) [9] for use in adults�18 years old and received conditional approval
by the European Medicines Agency [10]. It was prequalified by the World Health Organization
(WHO) [11] and is recommended by the WHO Strategic Advisory Group of Experts on
Immunization (SAGE) for high-risk populations in response to the 2018 to 2020 outbreak in
the DRC [12].
Recently, the heterologous 2-dose regimen of Ad26.ZEBOV (Zabdeno) and MVA-BN-Filo
(Mvabea) received approval by the European Commission under exceptional circumstances
for use in children and adults [13]. This regimen is recommended by WHO SAGE for prophy-
laxis and evaluation in lower-risk populations [12]. Following WHO SAGE recommendation,
the heterologous regimen is being studied in the DRC and in an ongoing vaccination cam-
paign in Rwanda in response to the 2018 to 2020 outbreak [14].
In Phase I studies, this regimen had an acceptable safety profile and was immunogenic in
healthy 18- to 50-year-old volunteers in England [15], Kenya [16], and Tanzania and Uganda
[17], inducing both humoral and cellular immune responses against EBOV GP. These data
encouraged further evaluation in Phase II and III studies.
We present a Phase II study to determine the safety, tolerability, and immunogenicity of
this heterologous 2-dose regimen, with various intervals between the 2 doses in the target pop-
ulation, i.e., healthy African adults, adolescents, and children. We also included a cohort of
HIV-infected adults to ensure that the vaccine regimen is safe and immunogenic in this popu-
lation. Finally, we explored the effect of an Ad26.ZEBOV booster vaccination administered 1
year post-dose 1 in a subset of healthy adults. This paper presents the results from the healthy




This Phase II randomised, observer-blind, placebo-controlled study was conducted in 7
sites in Africa [Burkina Faso (Bobo-Dioulasso, Banfora); Côte d’Ivoire (Abidjan, Toupah/
Ousrou); Kenya (Nairobi); Uganda (Masaka, Kampala)] between November 2015 and Feb-
ruary 2019. The protocol was approved by local and national independent Ethics Commit-
tees and Institutional Review Boards, and the study was done according to the Declaration
of Helsinki and International Conference on Harmonisation Good Clinical Practice Guide-
lines. All adult participants supplied written informed consent before enrolment. An inde-
pendent data monitoring committee was established to assess the safety data regularly
during the study. The study was registered at ClinicalTrials.gov NCT02564523. The study
protocol, including the CONSORT checklist, can be found in S1 Study Protocol and S1
CONSORT Checklist.
The primary objective was to assess the safety and tolerability of 3 vaccination schedules
with Ad26.ZEBOV administered on Day 1 and MVA-BN-Filo on Days 29, 57, or 85 in healthy
African adults, and of 2 schedules with Ad26.ZEBOV on Day 1 and MVA-BN-Filo on Days 29
or 57 in HIV-infected African adults. Secondary objectives included immunogenicity assess-
ments such as EBOV GP–specific immunoglobulin G (IgG) binding antibodies 21 days post-
dose 2 in healthy and HIV-infected adults, and the safety and tolerability of an Ad26.ZEBOV
booster dose on Day 365 in a subset of 90 healthy adults. Exploratory objectives included
assessments of binding antibodies at other time points in healthy (including after the booster
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dose) and HIV-infected adults and measurement of EBOV GP–specific neutralising antibodies
and cellular immune responses in subsets of healthy adults.
Study participants, randomisation, and blinding
Study participants were recruited from the general population and from HIV–positive
cohorts in Africa. Information regarding the study was shared through community meet-
ings, posters, and public conferences where volunteers were invited to study sites. After
screening by the investigators at study sites, eligible healthy adults aged 18 to 70 years were
randomised to 3 groups (1:1:1) in parallel using randomly permuted blocks. Groups 1, 2,
and 3 correspond to 28-, 56-, and 84-day intervals, respectively. For the healthy adult
cohort, there was stratification by age (18 to 50 years and >50 years). The interactive web
response system (IWRS; prepared by Signant Health) assigned a unique code, which dic-
tated the assignment and matching vaccination schedule for a participant. These codes were
maintained within the IWRS and were not provided to the investigators. During the study
pause (detailed in the results section), investigators were instructed not to proceed with any
randomisation until the pause was lifted.
Healthy adults were enrolled in parallel to Groups 1 to 3 until a target of 132 participants
had been randomised to Group 3. Further enrolment continued to Groups 1 and 2 with 1:1
randomisation until each group contained 264 participants. When 7-day safety data were
available from 25% of healthy adults, enrolment of the HIV-infected cohort started, consisting
of 142 HIV-infected adults aged 18 to 50 years randomised 1:1 to 2 groups to receive the 2 vac-
cinations with a 28- or 56-day interval. Participants in each of the 5 groups in healthy and
HIV-infected cohorts were further randomised 5:1 to receive active vaccines or placebo in the
different regimens. The first 90 healthy adult participants in Groups 1 and 2 (vaccinees, n = 73
or placebo, n = 17) who provided consent received an Ad26.ZEBOV booster dose or placebo
on Day 365. Participants, investigators, and study staff remained blinded to the allocation of
investigational products throughout the study. Vaccines and placebo were prepared by a site
pharmacist who was the only unblinded member of staff. The pharmacist received the rando-
misation number and allocated the right study vaccine to the participant. Masking tape was
used to cover the dispensing syringes containing the study vaccine/placebo allocated to each
study participant.
Eligible volunteers were confirmed healthy based on physical examination, ECG, vital
signs, and clinical laboratory assessments performed at screening and their medical history.
HIV-infected volunteers had to have been diagnosed at least 6 months previously, have a
CD4+ cell count>350 cells/μL, be in an otherwise reasonably good medical condition without
an AIDS-defining diagnosis or a clinically significant disease, and be on a stable regimen of
antiretroviral therapy. Full details of inclusion and exclusion criteria are supplied in S1 Text.
Sample size determination
The overall planned sample size for healthy and HIV-infected cohorts included 792 partici-
pants who were to receive either the 2-dose heterologous vaccination regimen of Ad26.
ZEBOV and MVA-BN-Filo or placebo to substantially contribute to the overall safety database
of the regimen. In the healthy adult cohort, a total of 550 participants were to receive Ad26.
ZEBOV and MVA-BN-Filo across the different vaccination schedules (220 participants in
28-day interval and 220 participants in 56-day interval; 110 in 84-day interval); 110 partici-
pants were to receive placebo. The preplanned smaller sample size target for Group 3 (84-day
interval) was selected to provide preliminary information on the effect of a longer interval
between doses. The larger sample size target for Groups 1 and 2 was reflective of the schedules
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for which an indication was being sought. As the study was not powered to test statistical dif-
ference between the groups, we consider that these differences in recruitment are unlikely to
impact the conclusions of the study. In the HIV-infected adult cohort, a total of 110 partici-
pants were to receive Ad26.ZEBOV and MVA-BN-Filo across the different vaccination sched-
ules (55 participants in 28-day interval and 55 in 56-day interval); 22 participants were to
receive placebo. Sample size determination was not based on formal statistical hypothesis test-
ing. However, in case a specific adverse event (AE) was not observed, the one-sided 97.5%
upper confidence limit of the true incidence rate of this AE was less than 6.5%, 3.3%, 1.7%, and
0.7% for a sample size of 55, 110, 220, and 550 participants, respectively.
Vaccines
Ad26.ZEBOV is a monovalent, recombinant, replication-incompetent adenovirus 26-vectored
vaccine encoding EBOV Mayinga variant GP. MVA-BN-Filo is a multivalent, recombinant,
nonreplicating, modified vaccinia Ankara-vectored vaccine encoding EBOV Mayinga, Sudan
virus Gulu, and Marburg virus Musoke variant GPs, as well as Taï Forest virus nucleoprotein
[15–17].
Ad26.ZEBOV vaccination with 5 × 1010 viral particles on Day 1 was followed by 1 × 108
infectious units of MVA-BN-Filo on Day 29 (Group 1), Day 57 (Group 2), or Day 85 (Group
3). The booster vaccination (Day 365) consisted of Ad26.ZEBOV 5 × 1010 viral particles or pla-
cebo. Both vaccines and placebo (0.9% saline) were administered by intramuscular injection
(0.5 mL) in the deltoid. The second injection was administered in the opposite arm to the first
injection.
Safety and tolerability assessments
All participants were assessed at 30 and 60 minutes after each vaccination for any immediate
AEs. Participants were supplied with diary cards, rulers, and thermometers to measure and
record solicited local and systemic AEs and daily body temperature each evening for 7 days.
AEs were graded as 1 (mild), 2 (moderate), or 3 (severe) according to the adapted Division of
AIDS (DAIDS) Table (2017) [18]. Laboratory assessments of haematology and serum chemis-
try were done at screening, prevaccination, and 7 days after vaccination and graded according
to the FDA toxicity grading scale for healthy adult and adolescent volunteers enrolled in pre-
ventive vaccine clinical trials [19]. Any unsolicited AEs, until 42 days after the second vaccina-
tion or 28 days after the booster dose, were documented by the investigator. Any serious AEs
(SAEs) were recorded throughout the study, with follow-up to 1 year after the last vaccination
or event resolution as appropriate.
Immunogenicity assessments
Serum samples obtained from all participants at 4 time points were used to assess humoral
immune responses as binding IgG antibodies specific to EBOV GP: before the first vaccination
on Day 1 and the second vaccination on Days 29, 57 or 85, and 21 days post-dose 2, with a
final sample on Day 365 to assess persistence of antibodies. In the booster subset, additional
blood samples were obtained 4, 7, 21, and 365 days after receiving the booster dose. EBOV
GP–specific binding antibodies were measured at all time points using an EBOV GP Filovirus
Animal Non-Clinical Group (FANG) enzyme-linked immunosorbent assay (ELISA) [20] per-
formed at Q2 Solutions (San Juan Capistrano, CA, USA).
Virus neutralising antibodies were measured in a subset (19%; n = 100/536 [n = 50/268
assigned to the 28-day interval regimen; n = 50/268 assigned to the 56-day interval regimen])
of healthy adults on Day 1, 21 days after MVA-BN-Filo and at 1 year using the EBOV GP
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pseudovirion neutralisation assay (psVNA) at Monogram (San Francisco, CA, USA) (S2 and
S3 Texts). Levels of neutralising antibodies to the Ad26 vector were measured using an
Ad26-specific virus neutralisation assay (Ad26 VNA) in a subset (19%; n = 100/536 [n = 50/
268 assigned to the 28-day interval regimen; n = 50/268 assigned to the 56-day interval regi-
men]) of healthy adults and in all HIV-infected participants before vaccination on Day 1 and
again on Day 365 (pre-booster) for healthy adults (Janssen Vaccines and Prevention, Leiden,
the Netherlands). Intracellular cytokine staining (ICS) and interferon gamma (IFNγ) enzyme-
linked immunospot (ELISpot) assays were done in a subset of healthy (16%; n = 84/536
[n = 46/268 assigned to the 28-day interval regimen; n = 38/268 assigned to the 56-day interval
regimen]) and HIV-infected (21%; n = 15/71 assigned to the 56-day interval regimen) partici-
pants (see S2 Text for selection criteria) on Day 1, 21 days post-dose 2 and 1 year post-dose 1
(HIV Vaccine Trials Network, Seattle, WA, USA), as previously described [15–17,21].
Statistical analyses
The study was originally designed as a prospective study with no formal hypothesis testing.
Safety analyses were descriptive, based on the full analysis set consisting of all participants who
received at least 1 dose of active vaccine or placebo regardless of protocol deviations. The main
immunogenicity analysis is based on the per-protocol analysis set. It included all randomised
and vaccinated participants who received both vaccinations in the protocol-defined windows,
had at least 1 evaluable immunogenicity sample post vaccination, and no major protocol devi-
ations influencing the immune response. A sensitivity analysis was conducted for those who
received their second vaccination outside the protocol-defined windows. These participants
were part of the immunogenicity analysis set that included all randomised and vaccinated par-
ticipants who had at least 1 postvaccination (i.e., after date of vaccination) evaluable immuno-
genicity sample. Binding antibody results were expressed as group geometric mean
concentrations (GMCs) of ELISA units with 95% confidence intervals (CIs) at each time point
and responder rates, i.e., the percentage of each group with post-vaccination concentrations
>2.5-fold the lower limit of quantification [LLOQ; 36.11 ELISA units/mL (EU/mL)] in base-
line seronegative individuals or >2.5-fold the baseline value in initially seropositive partici-
pants. All values below the LLOQ were imputed with half the LLOQ value. Exploratory
analysis responder definitions are reported in S4 Text. A Spearman correlation coefficient was
calculated for EBOV GP–specific binding antibody concentrations (FANG ELISA) and
psVNA titres 21 days post-dose 2.
While no formal statistical testing was originally planned, statistical analyses were per-
formed post hoc for primary outcomes. The statistical significance was set at p-value < 0.05.
No test multiplicity adjustments were generally performed.
Results
Participant enrolment and clinical hold
Enrolment of participants began on 9 November 2015 and was paused on 28 April 2016 to per-
mit a thorough investigation of 2 SAEs that occurred in a concomitant study in Europe [22].
At the time of the pause, more than 200 healthy participants had been enrolled, some awaiting
their first vaccination, and some already having received the first vaccine. When the indepen-
dent data monitoring committee and the regulatory authorities agreed to continuation of the
study (clinical hold lifted by US FDA on 16 June 2016), participants who had already received
1 dose before the clinical hold were offered the second vaccination out-of-window but were
excluded from the per-protocol analysis set. Those who had been enrolled but had not received
their first vaccination were rescreened and vaccinated according to their preassigned study
PLOS MEDICINE Phase II trial of Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in Africa
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schedule. Vaccination of the HIV-infected participants only started after lifting the clinical
hold. Monitoring was continued for all participants up to the 365-day follow-up, irrespective
of their inclusion in the per-protocol analysis set. The date of last participant last visit was 12
February 2019.
Baseline demographics
The full analysis set included 668 healthy adults (559 vaccinees, 109 placebo) and 142
HIV-infected adults (118 vaccinees, 24 placebo), who received at least 1 dose of Ad26.
ZEBOV or placebo (Fig 1). Participant demographic data are shown in Table 1. Among
these, 400 healthy adults and 140 HIV-infected adults were included in the per-protocol
analysis set (Table 1).
Safety
Safety analyses are based on the full analysis set. There were 27 SAEs (which occurred in 24
participants) including 1 death overall during the study (Table A in S1 Data). One HIV-
infected participant died due to alcohol poisoning more than 4 weeks after receipt of
MVA-BN-Filo. No SAE was considered to be vaccine-related by the investigators.
Both vaccines were well tolerated in healthy and HIV-infected adults (Table 2). Reactogeni-
city results were similar when healthy adults were stratified to 18 to 50 years and>50 years age
groups (Table B in S1 Data).
Safety of 2-dose vaccination primary regimen. Overall, in healthy adults, solicited local
AEs were reported in 307/559 (54.9%), 296/517 (57.2%), 47/109 (43.1%), and 34/99 (34.3%)
participants following Ad26.ZEBOV, MVA-BN-Filo, first placebo, and second placebo injec-
tions, respectively. The most common solicited local AE was mild or moderate injection-site
pain. In HIV-infected adults, solicited local AEs were reported in 69/118 (58.5%), 51/117
(43.6%), 6/24 (25.0%), and 4/24 (16.7%) participants following Ad26.ZEBOV, MVA-BN-Filo,
first placebo, and second placebo injections, respectively. The event rate following Ad26.
ZEBOV in healthy adults (54.9%) was not statistically different (p-value = 0.54) from that of
the HIV-infected adults (58.5%; Table C in S1 Data); following MVA-BN-Filo, a significant
difference (57.2% versus 43.6%, respectively, p-value = 0.01) was observed. In the healthy
Fig 1. Study disposition of healthy adults and HIV-infected adults. n = number of participants.
https://doi.org/10.1371/journal.pmed.1003813.g001
PLOS MEDICINE Phase II trial of Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in Africa
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003813 October 29, 2021 8 / 22
adults, 2/559 (0.4%) and 4/517 (0.8%) participants reported Grade 3 local AEs following Ad26.
ZEBOV and MVA-BN-Filo injections, respectively; no Grade 3 local AEs were reported by
placebo recipients or HIV-infected adults.
In healthy adults, solicited systemic AEs were reported in 361/559 (64.6%), 306/517 (59.2%),
67/109 (61.5%), and 49/99 (49.5%) participants following Ad26.ZEBOV, MVA-BN-Filo, first
placebo, and second placebo injections, respectively. The most frequent systemic AEs were
fatigue, headache, and myalgia. Compared to the healthy adults, there was no significant differ-
ence (p-value = 0.53 following Ad26.ZEBOV; p-value = 0.06 following MVA-BN-Filo; Table C
in S1 Data) in reactogenicity profile in HIV-infected adults in whom systemic AEs were
reported in 80/118 (67.8%), 58/117 (49.6%), 9/24 (37.5%), and 10/24 (41.7%) participants fol-
lowing Ad26.ZEBOV, MVA-BN-Filo, first placebo, and second placebo injections, respectively.
Grade 3 systemic AEs were reported in 0% to 4.2% of healthy and HIV-infected adults follow-
ing Ad26.ZEBOV, MVA-BN-Filo, or placebo injections.
In healthy adults, fever (�38.0˚C) occurred in 25/559 (4.5%), 33/517 (6.4%), 4/109 (3.6%),
and 3/99 (3.0%) participants following Ad26.ZEBOV, MVA-BN-Filo, first placebo, and second
placebo injections, respectively. Grade 3 fever (>38.9˚C) was reported in 4/559 (0.7%), 9/517
(1.7%), 0/109 (0.0%), and 1/99 (1.0%) participants following Ad26.ZEBOV, MVA-BN-Filo, first
placebo, and second placebo injections, respectively (Table D in S1 Data). In HIV-infected par-
ticipants, fever was reported in 13/118 (11.0%), 3/117 (2.6%), 2/24 (8.3%), and 3/24 (12.5%) par-
ticipants following Ad26.ZEBOV, MVA-BN-Filo, first placebo, and second placebo injections,
respectively. The fever rate following Ad26.ZEBOV in healthy adults (4.5%) was statistically
lower (p-value = 0.01) than that of the HIV-infected adults (11.0%; Table C in S1 Data);
Table 1. Baseline characteristics of the participants in the full analysis set.�
Healthy adults HIV-infected adults












N = 225 43 224 44 110 22 59 12 59 12
Sex, n (%)
Male 152 (67.6) 28 (65.1) 153 (68.3) 28 (63.6) 83 (75.5) 14 (63.6) 20 (33.9) 4 (33.3) 17 (28.8) 2 (16.7)
Female 73 (32.4) 15 (34.9) 71 (31.7) 16 (36.4) 27 (24.5) 8 (36.4) 39 (66.1) 8 (66.7) 42 (71.2) 10 (83.3)
Ethnicity‡, n (%)
Black 223 (99.1) 42 (97.7) 224 (100) 43 (97.7) 109 (99.1) 22 (100) 59 (100) 12 (100) 59 (100) 12 (100)
Asian 2 (0.9) 1 (2.3) 0 0 1 (0.9) 0 0 0 0 0
White 0 0 0 1 (2.3) 0 0 0 0 0 0
Age (years)
Mean (SD) 33.3 (12.4) 32.0 (10.4) 33.3 (11.5) 33.3 (11.6) 31.4 (11.5) 33.7 (12.3) 38.8 (6.6) 34.3 (7.7) 39.0 (6.7) 42.1 (5.0)
Median (range) 29.0 (18–69) 30.0 (19–60) 30.0 (18–66) 30.0 (18–65) 27.0 (18–67) 31.0 (19–66) 40.0 (21–49) 36.5 (22–48) 39.0 (18–49) 41.5 (34–50)
Body mass index (kg/m2)
Mean (SD) 23.0 (3.95) 23.4 (4.55) 23.4 (3.65) 22.9 (4.18) 23.0 (4.29) 25.1 (6.10) 24.5 (4.51) 23.0 (3.88) 24.0 (4.51) 24.5 (3.78)
Per-protocol analysis set#
N# = 173 32 137 24 27 7 58 11 59 12
�Participants who received at least 1 dose of the study vaccines or placebo.
‡Ethnicity was recorded as race within the database.
#The numbers of participants who received the study vaccines or placebo within the predefined time windows and supplied at least 1 postvaccination sample with no
protocol deviations.
N, number of participants who received at least 1 dose of the study vaccines or placebo; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003813.t001
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Table 2. Solicited and unsolicited AEs in the full analysis set after each vaccination dose, no. (%).�
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following MVA-BN-Filo, no statistically significant difference (6.4% versus 2.6%, respectively,
p-value = 0.12) was observed.
Grade 3 fever was reported in 3/118 (2.5%) participants following Ad26.ZEBOV injections,
1/24 (4.2%) participants following second placebo injections and in no participants following
MVA-BN-Filo or first placebo injections.
In healthy adults, unsolicited AEs were reported at similar rates in each group; reported in
201/559 (36.0%), 166/517 (32.1%), 40/109 (36.7%), and 35/99 (35.4%) participants following
Ad26.ZEBOV, MVA-BN-Filo, first placebo, and second placebo injections, respectively. The
most frequent unsolicited AEs were malaria and upper respiratory tract infections (URTIs). The
rates of unsolicited AEs reported in HIV-infected adults were 50/118 (42.4%), 44/117 (37.6%),
10/24 (41.7%), and 8/24 (33.3%) in participants following Ad26.ZEBOV, MVA-BN-Filo, first
placebo, and second placebo injections, respectively. Compared to the healthy adults, the
observed rates in HIV-infected adults were not significantly different following either vaccine
(p-value = 0.21 following Ad26.EBOV; p-value = 0.28 following MVA-BN-filo; Table C in S1
Data). The most frequent unsolicited AEs in the HIV-infected adults were URTI and cases of
neutropaenia, which were reported equally in vaccine and placebo arms.
Safety of booster dose. There was no apparent exacerbation of reactogenicity after the
booster dose of Ad26.ZEBOV in healthy adults. Of these 73 participants, 34 (46.6%) and 35
(47.9%) reported local or systemic AEs, respectively, of which only one was Grade 3 (fever).
Immunogenicity
Overall, immunogenicity results were similar when healthy adults were stratified to 18 to 50
years and>50 years age groups (Table E in S1 Data).
Binding antibody responses against EBOV GP. The immunogenicity analyses were
based on the participants in the per-protocol analysis set. Binding antibodies in all placebo
groups were very low or undetectable at all time points.
After Ad26.ZEBOV vaccination of healthy adults, there were marked increases in EBOV
GP–specific binding antibodies (Fig 2A). Prior to dose 2 vaccination, levels at Days 29, 57,
and 85 in Groups 1, 2, and 3, respectively, were similar with GMCs of 332 EU/mL (95% CI
282 to 390), 361 EU/mL (95% CI 307 to 423), and 242 EU/mL (95% CI 181 to 323) (Fig 2A).
The proportion of responders was 77%, 80%, and 81%, respectively (Table F in S1 Data).
MVA-BN-Filo vaccination elicited further increases in antibody concentrations, reaching
GMCs of 3,085 EU/mL (95% CI 2,648 to 3,594), 7,518 EU/mL (95% CI 6,468 to 8,740), and
7,300 EU/mL (95% CI 5,116 to 10,417) in the 28-, 56-, and 84-day interval groups, respectively,
21 days post-dose 2 (Fig 2A). The GMCs of binding antibodies were statistically different for
Table 2. (Continued)

















�Solicited local and systemic AEs were recorded on diary cards by participants for 7 days and unsolicited AEs until Day 28 after each vaccination. Solicited local AEs
included pain, erythema, swelling, and pruritis; systemic AEs included nausea/vomiting, fatigue/malaise, headache, myalgia, arthralgia, and chills.
‡Grade 3 was defined as symptoms causing inability to perform usual social and functional activities.
Vaccines: Ad26 = Ad26.ZEBOV at a dose of 5 × 1010 vp; MVA = MVA-BN-Filo at a dose of 1 × 108 Inf.U.
AE, adverse event; N, number of participants with data at that time point; n (%), number (percentage) of participants with one or more events; NA, not applicable.
https://doi.org/10.1371/journal.pmed.1003813.t002
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the 28- and 56-day interval groups (GMC ratio [95% CI] = 0.4 [0.3 to 0.5], p-value< 0.001) and
the 28- and 84-day interval groups (GMC ratio [95% CI] = 0.4 [0.3 to 0.7], p-value< 0.001) but
not for 56- and 84-day interval groups (GMC ratio [95% CI] = 1.0 [0.6 to 1.6], p-value = 1.00;
Table G in S1 Data). At this time, responder rates were 98%, 99%, and 100%, respectively
(Table F in S1 Data). At Day 365, binding antibodies persisted with GMCs ranging from 313
to 363 EU/mL in 80%, 78%, and 88% of participants in the 28-, 56-, and 84-day groups, respec-
tively (Fig 2A and Table F in S1 Data); the GMCs were not statistically different for the interval
groups (Table G in S1 Data).
In the 28- and 56-day groups of HIV-infected adults, patterns of responses were similar to
those in healthy adults in terms of kinetics and magnitude (Fig 2B). Prior to dose 2, binding anti-
body responses were observed in 81% and 88% participants, with GMCs of 368 EU/mL (95% CI
272 to 497) and 291 EU/mL (95% CI 233 to 364) in the 28- and 56-day regimens, respectively
(Table H in S1 Data). At 21 days post-dose 2, there was no evidence of a statistical difference in
GMCs of binding antibodies (GMC ratio [95% CI] = 0.8 [0.6 to 1.1], p-value = 0.22) between the
groups (Table G in S1 Data). The GMCs were 4,207 EU/mL (95% CI 3,233 to 5,474) and 5,283
EU/mL (95% CI 4,094 to 6,817) with 100% responder rates in the 28- and 56-day groups. At
Day 365, antibodies persisted in 86% and 88% HIV-infected participants in the 28- and 56-day
groups, respectively, with GMCs of 459 EU/mL (95% CI 352 to 600) and 338 EU/mL (95% CI
253 to 450) (Table H in S1 Data); no statistically significant difference (GMC ratio [95% CI] =
1.4 [0.9 to 2.0], p-value = 0.12) was observed between regimens. Compared to the healthy adults,
the GMCs of binding antibodies at 21 days post-dose 2 were statistically different for the HIV-in-
fected adults for both intervals (GMC ratio [95% CI] = 0.7 [0.5 to 0.99], p-value = 0.04 for 28-day
interval; GMC ratio [95% CI] = 1.4 [1.1 to 1.9], p-value = 0.02 for 56-day interval; Table I in
S1 Data).
Response to booster dose. In subsets of healthy participants from the 28- and 56-day
interval groups, an Ad26.ZEBOV booster dose on Day 365 elicited anamnestic responses in
both groups. GMCs rapidly increased, and, 7 days post-booster, levels were higher than after
the initial Ad26.ZEBOV, MVA-BN-Filo regimen; 21 days post-booster, GMCs were 29,315
EU/mL (95% CI 20,614 to 41,689) in the 28-day group and 41,643 EU/mL (95% CI 32,045 to
54,116) in the 56-day group (Table F in S1 Data). In both groups, responses persisted in 97%
to 100% of participants 1 year post-booster (Day 729) with similar GMCs (95% CI 4,383 to
4,534 EU/mL).
Out-of-protocol window. Among healthy participants, 204 (n = 169, active; n = 35, pla-
cebo) received their second dose outside the protocol-defined window. A sensitivity analysis of
their binding antibody responses demonstrated that increases in the time interval between
first and second doses from 99 to 483 days did not appear to negatively impact the immune
response post-dose 2. After Ad26.ZEBOV vaccination, before MVA-BN-Filo vaccination,
GMCs were maintained at similar levels for groups in which the interval was extended up to
140 days (266 EU/mL [95% CI 198 to 358]), 196 days (197 EU/mL [95% CI 159 to 245]), 252
days (239 EU/mL [95% CI 195 to 293]), or� 280 days (212 EU/mL [95% CI 121 to 372])
(Table J in S1 Data). There was a trend for increasing responses 21 days after MVA-BN-Filo
Fig 2. Anti-EBOV GP binding antibody responses. (A) Healthy adults administered Ad26.ZEBOV on Day 1 and MVA-BN-Filo 28,
56, or 84 days later as indicated. Subsets of 28- and 56-day groups received Ad26.ZEBOV booster on Day 365. “Pre-booster”
indicates the pre-booster vaccination measurement observed in participants who received the booster vaccination. (B) HIV-infected
adults administered with Ad26.ZEBOV on Day 1 and MVA-BN-Filo 28 or 56 days later, as indicated. Responses are expressed as
GMCs (ELISA units/mL, 95% CI). Responses in placebo groups are shown as open symbols. Black dotted line represents the LLOQ.
The points (symbols) denote GMCs, and error bars denote 95% CIs. Vaccines: Ad26 = Ad26.ZEBOV at a dose of 5 × 1010 vp;
MVA = MVA-BN-Filo at a dose of 1 × 108 Inf.U. CI, confidence interval; GMC, geometric mean concentration; LLOQ, lower limit
of quantification.
https://doi.org/10.1371/journal.pmed.1003813.g002
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vaccination as the interval lengthened. GMCs were 15,555 EU/mL (95% CI 10,907 to 22,184,
n = 17) for 140 days, 14,995 EU/mL (95% CI 11,855 to 18,965, n = 52) for 196 days, 16,149
EU/mL (95% CI 13,882 to 18,786, n = 77) for 252 days, and 23,897 EU/mL (95% CI 16,703 to
34,188, n = 21) for intervals of�280 days (Table J in S1 Data).
Neutralising antibody responses against EBOV GP. Neutralising antibodies against
EBOV GP were tested in a subset of per-protocol analysis set healthy adult participants: 76 vac-
cinees and 21 placebo recipients (Table K in S1 Data). Neutralising antibodies were not
observed in placebo recipients at any time point. At 21 days post-dose 2, 92% and 97% in the
28- and 56-day regimens, respectively, demonstrated neutralising antibodies against EBOV
GP; geometric mean titres (GMTs) were 982 half maximal inhibitory concentration (IC50)
(95% CI 714 to 1,350) and 4,100 IC50 (95% CI 2,927 to 5,745) (Fig 3 and Table K in S1 Data).
Titres decreased by Day 365 with 21% and 24% of the tested 28- and 56-day group participants,
respectively, still displaying neutralising activity; GMTs were 123 IC50 (95% CI <LLOQ–165)
and 153 IC50 (95% CI <LLOQ–210). There were strong correlations between the neutralising
and binding antibody responses 21 days post-dose 2 (Spearman coefficient = 0.735 in 28-day
interval group and 0.852 in 56-day interval group) and at Day 365 (Spearman coeffi-
cient = 0.746 in 28-day interval group and 0.631 in 56-day interval group) (S1 Fig).
Neutralising antibody responses against Ad26 vector. Before vaccination, Ad26-specific
neutralising antibodies were analysed in 98 healthy adults: 48 of the 28-day group (39 vaccinees,
Fig 3. Anti-EBOV GP neutralising antibody responses in healthy adults. The error bars represent the GMT (IC50) and its 95% CI. Subset of
healthy adults administered with Ad26.ZEBOV on Day 1 and MVA-BN-Filo 28 or 56 days later as indicated. Responses in placebo groups are
shown as open symbols. Black dotted line represents the LLOQ. Vaccines: Ad26 = Ad26.ZEBOV at a dose of 5 × 1010 vp; MVA = MVA-BN-Filo at
a dose of 1 × 108 Inf.U. CI, confidence interval; GMT, geometric mean titre; IC50, half maximal inhibitory concentration; LLOQ, lower limit of
quantification.
https://doi.org/10.1371/journal.pmed.1003813.g003
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9 placebo) and 50 of the 56-day group (38 vaccinees and 12 placebo). An overall Ad26-specific
seroprevalence rate of 91% with a GMT of 106 IC90 (95% CI 79 to 142) was detected. Similarly,
an overall 83% seroprevalence rate (GMT: 73 IC90) was observed for the HIV-infected adults
(Table L in S1 Data). Potential impact of Ad26-specific preexisting neutralising antibodies on
vaccine-induced EBOV GP–specific humoral immune responses was examined at a participant
level via descriptive statistical correlation analyses (S2 and S3 Figs). Negligible correlations
were observed between Ad26-specific neutralising antibody titres at baseline and EBOV GP–
specific binding antibody concentrations 21 days post-dose 2 (Spearman correlation coeffi-
cients: −0.02 and 0.22 for 28- and 56-day intervals in healthy participants, respectively; 0.02 and
0.01 for 28- and 56-day intervals in HIV-infected participants, respectively), as well as EBOV
GP–specific neutralising antibody titres 21 days post-dose 2 (Spearman correlation coefficients:
−0.15 and 0.11 for 28- and 56-day intervals, respectively).
Cellular immune responses against EBOV GP
Cellular immune responses were tested in a subset of healthy (16%) and HIV-infected (21%)
participants. Twenty-one days post-dose 2, CD4+ T cell responses were observed in 32%
(56-day interval) and 50% (28-day interval) of healthy participants. The median value tended
to be numerically higher in participants vaccinated in the 28-day interval (0.11%) than the
56-day interval (0.06%) (S4A Fig). At the same time point, CD8+ T cell responses were
detected in 29% (28-day interval) and 30% (56-day interval) of healthy participants (median
value: 0.05%; <threshold, respectively) (S4B Fig).
In HIV-infected participants (56-day interval), 21 days post-dose 2, CD4+ T cell responses
were observed in 40% of participants (median 0.18%). CD8+ T cell responses were observed in
17% of participants (median value <threshold) (S5A and S5B Fig). IFNγ ELISpot data
(Table M in S1 Data) are described in S5 Text.
Discussion
This Phase II study confirmed the safety, tolerability, and immunogenicity of heterologous
2-dose Ad26.ZEBOV, MVA-BN-Filo vaccination regimen against EBOV in African adults,
including those with HIV infection. Safety and tolerability profiles were consistent with those
observed in Phase I studies in European and African populations [15–17] and a Phase II study
in a European population [22]. There were no deaths or SAEs associated with vaccination.
Most AEs associated with either vaccine were transient and mild to moderate in severity, con-
sisting mainly of injection-site pain, fatigue, headache, and myalgia.
As many conditions can influence the response to Ebola vaccines [23], it is important to
ensure that local factors do not affect responses to vaccines. We previously reported the
immune responses to the Ad26.ZEBOV, MVA-BN-Filo heterologous 2-dose regimen in Phase
I studies in African populations [16,17]. The present study confirms these data and further
demonstrates that HIV infection (well controlled by highly active antiretroviral therapy), a
condition prevalent in African populations that could be expected to influence vaccine effi-
cacy, did not have any apparent influence on those immune responses. The magnitude of the
antibody responses 21 days post-dose 2 in our representative African population was similar
to that observed in a Phase II study performed in Europe with a similar design, with compara-
ble levels of EBOV GP–specific binding antibodies and virus neutralising activity 21 days post-
dose 2 with 28- and 56-day vaccination intervals, measured in the same laboratory [22].
We have also reported safety and immunogenicity data of the 2-dose heterologous Ad26.
ZEBOV and MVA-BN-Filo vaccination regimen, given 8 weeks apart, in a 2-stage trial in
Sierra Leone. This study was initially foreseen as a safety and clinical efficacy study but was
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amended to become a safety and immunogenicity study after waning of the outbreak in Sierra
Leone [24,25].
In addition, our study confirms the optimal interval between the 2 vaccinations, i.e., 56
days. Strong immune responses are observed with each of the 3 intervals tested, but increasing
the interval from 28 to 56 days resulted in 2-fold higher levels of binding antibodies in healthy
adults and 4-fold higher levels of neutralising antibodies. Prolonging the interval from 56 to 84
days did not further increase these immune responses, confirming the 56-day regimen as the
optimal choice to achieve a high-response magnitude with a reasonably short vaccination
schedule.
Some healthy adult participants either did not receive dose 2 or received dose 2 outside of
their protocol-defined interval. However, sensitivity analyses of immune responses among
participants who received their second vaccination “out-of-window” confirmed that extending
the interval between Ad26.ZEBOV and MVA-BN-Filo vaccinations to>280 days resulted in
immune responses that were at least as high in magnitude as the 56-day interval.
Although >90% of the adult participants had preexisting neutralising antibodies against the
Ad26 vector, there was no indication that this had any impact on the vaccine-induced immune
responses based on descriptive statistical analyses.
A mechanistic correlate of protection has not yet been determined, and there is no human
correlate of protection against EBOV infection. As demonstrated in nonhuman primate lethal
challenge models, EBOV GP–specific IgG binding antibodies correlated strongly with protec-
tion and, thus, can be considered as a measure of efficacy [26,27]. When measured from 10
days after a single dose of the rVSV-ZEBOV-GP vaccine in a ring vaccination strategy in the
2014 to 2016 and 2018 to 2020 outbreaks, protective efficacy was found to be 100% and 97.5%,
respectively [7,8]. This efficacy was achieved with an rVSV-ZEBOV-GP vaccine formulation
that has been reported to elicit a GMC of 1,262 EU/mL 28 days after vaccination in non-Afri-
can populations [28]. This GMC was measured using the same assay in the same laboratory as
our study, in which the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen elicited EBOV GP–spe-
cific antibody concentrations from 3,085 to 7,518 EU/mL 21 days after the second vaccination
in these African populations, depending on the interval between vaccinations.
One year post-Ad26.ZEBOV vaccination, binding antibodies were observed in 78% to 88%
of participants. An Ad26.ZEBOV booster dose at 1 year elicited strong anamnestic responses
with 55-fold increases in binding antibodies in both 28- and 56-day groups within 7 days of
the booster dose. This observation suggests that the 2-dose Ad26.ZEBOV, MVA-BN-Filo vac-
cine regimen had established immune memory [29] that could rapidly be reactivated, which
could be very important in the context of recurrent epidemics observed in Africa.
The numerous EBOV outbreaks in the DRC highlight the need for a prophylactic vaccine
against this virulent disease. Current WHO SAGE recommendations are to use the single-dose
rVSV-ZEBOV-GP vaccination for reactive use in those at high risk of contracting EBOV and
prophylactic use and evaluation of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo regi-
men for those at less imminent risk [12]. Our study adds to the database of knowledge about
this heterologous 2-dose strategy, particularly in the target population of African adults. The
finding that increasing the interval between vaccinations from 56 to 84 days (and even further)
resulted in similarly high binding antibody responses allows for potential flexibility in vaccina-
tions, which might be useful in practice. The second part of our study in paediatric participants
to ensure that the strategy is safe and immunologically effective in children as young as 4 years
of age will be published separately. Additional studies are already underway to further evaluate
the Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in African populations, including
younger children and infants, pregnant women, and healthcare workers who may have to
travel to regions recurrently affected by outbreaks such as in the DRC.
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Study limitations include that some healthy adult participants either did not receive dose 2
or received dose 2 outside of their protocol-defined interval. However, sensitivity analyses of
immune responses among participants who received their second vaccination “out-of-window”
showed that extending the interval between Ad26.ZEBOV and MVA-BN-Filo vaccinations to
>280 days resulted in immune responses that were at least as high in magnitude as the 56-day
interval. Another limitation is that the follow-up period was limited to 365 days for the majority
of participants, and so it was not possible to determine whether immune responses persisted
beyond this time period. However, this limitation could not be avoided as a follow-up period
had to be determined before commencing the study, and, reassuringly, modelling results [30]
suggest that immune responses persist beyond this time. Finally, no formal statistical testing of
safety or immune response data was originally planned for this study. Although post hoc statis-
tical comparisons were performed, no direct conclusions on the differences in safety and immu-
nogenicity observed between regimens or between healthy and HIV-infected groups can be
made; a clinically meaningful difference in terms of binding antibody levels is not known.
In conclusion, our study confirms that the heterologous 2-dose Ad26.ZEBOV, MVA-BN-
Filo vaccination regimen has a safety, tolerability, and immunogenicity profile in African
adults similar to that already demonstrated in European volunteers. These data supported the
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phouët-Boigny, Abidjan; members of the KAVI Institute of Clinical Research, University of
Nairobi (Nancy Thairu [Finance Manager], Dr Borna Nyaoke [Investigator], Dr Lavinia
Bwisa [Investigator], Bashir Farah [Laboratory Manager], Moses Mundia [Data Manager],
and Dorothy Essendi [Study Coordinator]); members of the Makerere University Walter
Reed Project, Kampala (Dr Salim Wakabi [PI], Maureen Mukyala [Study Coordinator],
Amir Wamala [PoR], Allan Tindikahwa [Regulatory and Compliance Manager], Dr Betty
PLOS MEDICINE Phase II trial of Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen in Africa
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003813 October 29, 2021 19 / 22
Mwesigwa [Sub-Investigator], and Ezra Musingye [Data Manager]); members of the MRC/
UVRI and LSHTM Uganda Research Unit, Entebbe (Prof. Pontiano Kaleebu [Co-PI], Dr
Jennifer Serwanga [Sub-Investigator/Immunologist], Dr Ggayi Abu-Baker Mustapher
[Sub-Investigator/Project Coordinator], Dr Jonathan Kitonsa [Sub-Investigator/Study Cli-
nician], Mr Paul Taire [Pharmacy Technician], Dr Laura Joan Nsangi [Sub-Investigator/
Study Clinician], Mr Vincent Basajja [Community Liaisons Officer], Mr Tobias Vudriko
[Safety Laboratory Technologist], Mr Ben Gombe [Immunology Laboratory Technologist],
Mr Hellen Kalungi [Study Nurse], Mr Francis Kasekende [Study Pharmacist], and Dr Mary
Nyantaro [Sub-Investigator/Study Clinician]); members of Centre Muraz, Bobo-Dioulasso
(Dr Lionel Wilfried Ouedraogo [Laboratory Manager], Dr Armel Poda [Sub-Investigator],
Dr Bachirou Tinto [Pharmacist], Dr Dramane Kania [Laboratory Manager], Dr Naalona
Sandrine Hien [Sub-Investigator], Dr Guekoun Lougue [Pharmacist], Dr Innocent Valea
[Coordinator], Pr Halidou Tinto [Coordinator], and Dr Ines Evelyne Da [Sub-Investiga-
tor]); members of Groupe de Recherche Action en Santé (GRAS)/Centre National de
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